Abattis Bioceuticals Corp.
ATTBF
$0.00
$0.000.00%
| 09/30/2019 | 06/30/2019 | 03/31/2019 | 12/31/2018 | 09/30/2018 | |
|---|---|---|---|---|---|
| Net Income | -24.89% | -413.06% | 88.72% | 97.71% | -671.43% |
| Total Depreciation and Amortization | 120.75% | 0.00% | 3.92% | 101.05% | -197.81% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 208,027.78% | 99.73% | -425.58% | -100.30% | 1,368.23% |
| Change in Net Operating Assets | -101.81% | 1,898.57% | 1,516.13% | 89.60% | 88.03% |
| Cash from Operations | -46.85% | 1,363.68% | 59.02% | 3.73% | 59.42% |
| Capital Expenditure | -2,208.33% | 90.84% | -227.50% | 85.35% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 201.29% | -- | -- | -- | 99.90% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,159.12% | -16.12% | 3,351.59% | 98.02% | -198.40% |
| Cash from Investing | 44.95% | -620.96% | 3,009.09% | 89.66% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -87.56% | -80.60% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -100.00% | -87.70% | -80.84% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 30.36% | -194.39% | 171.61% | 6.97% | -37.30% |
